Nevro (NVRO)
(Delayed Data from NYSE)
$5.10 USD
+0.39 (8.28%)
Updated Sep 12, 2024 04:00 PM ET
After-Market: $5.10 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth A Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$5.10 USD
+0.39 (8.28%)
Updated Sep 12, 2024 04:00 PM ET
After-Market: $5.10 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth A Momentum C VGM
Zacks News
Nevro (NVRO) Q2 Loss Wider Than Expected, Revenues Down Y/Y
by Zacks Equity Research
Nevro (NVRO) sees dismal segmental performance in Q2.
Earnings Preview: Nevro (NVRO) Q2 Earnings Expected to Decline
by Zacks Equity Research
Nevro (NVRO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why You Should Hold on to Nevro (NVRO) Stock Now
by Zacks Equity Research
Nevro (NVRO) is gaining traction from a fortified international footprint and solid prospects in the SCS market. However, severe rivalry is a lingering woe.
Should You Invest in the SPDR S&P Health Care Equipment ETF (XHE)?
by Zacks Equity Research
Sector ETF report for XHE
Nevro (NVRO) Down 3.6% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Nevro (NVRO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Nevro (NVRO) Q1 Loss Wider Than Expected, Revenues Down Y/Y
by Zacks Equity Research
Nevro's (NVRO) domestic and international revenues fall year over year in Q1.
Nevro (NVRO) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Nevro (NVRO) delivered earnings and revenue surprises of -119.70% and -6.09%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Nevro (NVRO) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Nevro (NVRO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Nevro (NVRO) Plagued by Issues in Australia & Stiff Rivalry
by Zacks Equity Research
Nevro's (NVRO) international sales get affected by weakness in Australia.
Nevro (NVRO) Q4 Loss Wider Than Expected, Revenues Beat
by Zacks Equity Research
Nevro's (NVRO) solid domestic and international performance aids Q4 results.
Nevro (NVRO) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Nevro (NVRO) delivered earnings and revenue surprises of -88.24% and 0.53%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Nevro (NVRO) Q4 Earnings Expected to Decline
by Zacks Equity Research
Nevro (NVRO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Nevro (NVRO) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Nevro (NVRO) delivered earnings and revenue surprises of -23.33% and 2.11%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Nevro (NVRO) Q3 Earnings Preview: What to Look Out For
by Zacks Equity Research
Nevro (NVRO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Nevro (NVRO) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Nevro (NVRO) delivered earnings and revenue surprises of -16.67% and -0.03%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Is the Options Market Predicting a Spike in Nevro (NVRO) Stock?
by Zacks Equity Research
Investors need to pay close attention to Nevro (NVRO) stock based on the movements in the options market lately.
Should You Buy Nevro (NVRO) Ahead of Earnings?
by Zacks Equity Research
Nevro (NVRO) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.
Nevro's (NVRO) Q2 Loss Wider than Expected, Revenues Beat
by Zacks Equity Research
Nevro's (NVRO) topline gains on continued global adoption of HF10 therapy. Rising operating expenses are major concerns.
Should You Buy Nevro (NVRO) Ahead of Earnings?
by Zacks Equity Research
Nevro (NVRO) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.
Nevro (NVRO) Surges: Stock Moves 11.4% Higher
by Zacks Equity Research
Nevro (NVRO) was a big mover last session, as the company saw its shares rise over 11% on the day.
Here's Why Shares of Nevro Corp. (NVRO) Jumped Today
by Megan Sanks
Shares of Nevro Corp. NVRO) climbed 10% in midday trading Wednesday after the company reported preliminary sales numbers for the second quarter of fiscal year 2017.
Medical Product Q1 Earnings on May 8: ITGR, OPK & More
by Zacks Equity Research
Let's take a look at the major Medical products stocks slated to release their first-quarter 2017 reports on May 8.
New Strong Buy Stocks for October 13th
by Indradip Ghosh
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Thursday